AI Generated Content

This may include content generated using AI tools. Glance teams are making active and commercially reasonable efforts to moderate all AI generated content. Glance moderation processes are improving however our processes are carried out on a best-effort basis and may not be exhaustive in nature. Glance encourage our users to consume the content judiciously and rely on their own research for accuracy of facts. Glance maintains that all AI generated content here is for entertainment purposes only.

Cipla partners ImmunoACT to launch CAR-T therapy for blood cancers in Africa

SUMMARY

AI Generated Content
  • Cipla partners ImmunoACT to launch CAR-T therapy in Africa.
  • Talicabtagene autoleucel targets blood cancers in select markets.
  • USFDA notes deficiencies at a manufacturing facility.
AD
Other Interesting Stories
AD